Toll-like Receptors 2 and 4 Mediate Abeta(1-42) Activation of the Innate Immune Response in a Human Monocytic Cell Line
Overview
Affiliations
The primary molecules for mediating the innate immune response are the Toll-like family of receptors (TLRs). Recent work has established that amyloid-beta (Abeta) fibrils, the primary components of senile plaques in Alzheimer's disease (AD), can interact with the TLR2/4 accessory protein CD14. Using antibody neutralization assays and tumor necrosis factor alpha release in the human monocytic THP-1 cell line, we determined that both TLR2 and TLR4 mediated an inflammatory response to aggregated Abeta(1-42). This was in contrast to exclusive TLR ligands lipopolysaccharide (LPS) (TLR4) and tripalmitoyl cysteinyl seryl tetralysine (Pam(3)CSK(4)) (TLR2). Atomic force microscopy imaging showed a fibrillar morphology for the proinflammatory Abeta(1-42) species. Pre-treatment of the cells with 10 microg/mL of a TLR2-specific antibody blocked approximately 50% of the cell response to fibrillar Abeta(1-42), completely blocked the Pam(3)CSK(4) response, and had no effect on the LPS-induced response. A TLR4-specific antibody (10 microg/mL) blocked approximately 35% of the cell response to fibrillar Abeta(1-42), completely blocked the LPS response, and had no effect on the Pam(3)CSK(4) response. Polymyxin B abolished the LPS response with no effect on Abeta(1-42) ruling out bacterial contamination of the Abeta samples. Combination antibody pre-treatments indicated that neutralization of TLR2, TLR4, and CD14 together was much more effective at blocking the Abeta(1-42) response than the antibodies used alone. These data demonstrate that fibrillar Abeta(1-42) can trigger the innate immune response and that both TLR2 and TLR4 mediate Abeta-induced tumor necrosis factor alpha production in a human monocytic cell line.
Inflammasomes in Alzheimer's Progression: Nrf2 as a Preventive Target.
Lopez-Hernandez R, de la Torre-Alamo M, Garcia-Bueno B, Baroja-Mazo A, Fenoy F, Cuevas S Antioxidants (Basel). 2025; 14(2).
PMID: 40002308 PMC: 11851705. DOI: 10.3390/antiox14020121.
Pathology of Amyloid-β (Aβ) Peptide Peripheral Clearance in Alzheimer's Disease.
Tsoy A, Umbayev B, Kassenova A, Kaupbayeva B, Askarova S Int J Mol Sci. 2024; 25(20).
PMID: 39456746 PMC: 11507512. DOI: 10.3390/ijms252010964.
Pramotton F, Spitz S, Kamm R Adv Sci (Weinh). 2024; 11(32):e2403892.
PMID: 38922799 PMC: 11348103. DOI: 10.1002/advs.202403892.
The role of CD56 NK cells in neurodegenerative disorders.
Rodriguez-Mogeda C, van Ansenwoude C, van der Molen L, Strijbis E, Mebius R, de Vries H J Neuroinflammation. 2024; 21(1):48.
PMID: 38350967 PMC: 10865604. DOI: 10.1186/s12974-024-03040-8.
Neuronal ApoE4 in Alzheimer's disease and potential therapeutic targets.
Zhang L, Xia Y, Gui Y Front Aging Neurosci. 2023; 15:1199434.
PMID: 37333457 PMC: 10272394. DOI: 10.3389/fnagi.2023.1199434.